Prostatic Neoplasms, Castration-Resistant Withdrawn Phase 2 Trials for Apalutamide (DB11901)

IndicationStatusPhase
DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02906605A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerTreatment